Nivolumab
Monoclonal antibody targets PDCD1
Regulatory milestones approvals, filings & regulatory actions · 32 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (30) | US (FDA) | OPDIVO | — | 2015-09-30 – 2026-03-20 | fda.gov ↗ |
| Approved | EU (EMA) | Opdivo | — | 2015-06-19 | europa.eu ↗ |
| Approved | US (FDA) | OPDIVO | — | 2014-12-22 | fda.gov ↗ |
Trials 1,497 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 029 trials | ||||||
| Phase 0 | NCT07319195 | Apr 2026 → Apr 2028 expected | breast cancer | Jennifer Zhang | Recruiting | No outcome recorded |
| Phase 0 | NCT07210632 | Mar 2026 → Mar 2030 expected | brain cancer, malignant glioma | Eben Rosenthal | Recruiting | No outcome recorded |
| Phase 0 | NCT07328087 | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05704933 | Jun 2023 → Jun 2024 | metastatic malignant neoplasm in the brain, metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT05188118 | Feb 2023 → Feb 2025 | renal cell carcinoma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 0 | NCT05498792 | Nov 2022 → Mar 2027 expected | melanoma | Fox Chase Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT04272333 | Oct 2021 → Mar 2022 | head and neck squamous cell carcinoma | Presage Biosciences | Terminated | No outcome recorded |
| Phase 0 | NCT04891718 | Sep 2021 → Jun 2022 | cancer | Presage Biosciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT04741997 | May 2021 → Apr 2027 expected | metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT05482451 | Mar 2021 → Feb 2025 overdue | — | China Medical University Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04581382 | Dec 2020 → Oct 2024 | melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT04223648 | Aug 2020 → Feb 2022 | melanoma | Yale University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT03519308 | Jul 2020 → Apr 2022 | malignant pancreatic neoplasm | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT04134325 | Sep 2019 → Apr 2025 overdue | Hodgkins lymphoma | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03970252 | Jul 2019 → May 2024 | pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03812562 | Feb 2019 → Oct 2023 | hepatocellular carcinoma | Northwestern University | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT03575598 | Aug 2018 → Feb 2020 | oral cavity squamous cell carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 0 | NCT03463408 | Jul 2018 → Aug 2026 overdue | sarcoma | University of Rochester | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03543969 | Jun 2018 → Dec 2024 overdue | cutaneous melanoma, skin carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03311958 | May 2018 → Jan 2024 | diffuse large B-cell lymphoma | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03316274 | May 2018 → Jun 2021 | AIDS, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 0 | NCT03526185 | Feb 2018 → Dec 2020 | metastatic melanoma | Yale University | Terminated | No outcome recorded Stop: Business |
| Phase 0 | NCT03224871 | Aug 2017 → Jan 2020 | non-small cell lung carcinoma | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT03238365 | Aug 2017 → Jul 2019 | head and neck carcinoma, laryngeal disorder | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03162731 | May 2017 → Sep 2020 | head and neck carcinoma, laryngeal disorder | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03143270 | Apr 2017 → Apr 2027 expected | liver cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02652455 | Mar 2016 → Aug 2020 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT02210117 | Nov 2014 → Dec 2026 expected | clear cell renal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1309 trials · 8 met primary · 2 missed | ||||||
| Phase 1 | NCT07848295 | Dec 2026 → Oct 2030 expected | clear cell renal carcinoma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07430202 | Oct 2026 → Oct 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT07476326 | Sep 2026 → Aug 2027 expected | melanoma | Biocon Biologics UK Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07664176 | Sep 2026 → Dec 2030 expected | atypical teratoid rhabdoid tumor, brain cancer, ependymoma, malignant glioma +1 | Children's National Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT07460765 | Jul 2026 → Apr 2030 expected | oral cavity squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07501117 | Jun 2026 → Jun 2029 expected | uveal melanoma | Inge Marie Svane | Recruiting | No outcome recorded |
| Phase 1 | NCT07075120 | Apr 2026 → Aug 2027 expected | hepatocellular carcinoma | University of Hawaii | Recruiting | No outcome recorded |
| Phase 1 | NCT07401875 | Mar 2026 → Nov 2027 expected | kidney cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07090148 | Mar 2026 → Oct 2030 expected | metastatic prostate carcinoma | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT07653503 | Jan 2026 → Dec 2027 expected | cervical carcinoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| Show all 309 trials opens the full record — a long page | ||||||
| Phase 1/2276 trials · 11 met primary · 4 missed | ||||||
| Phase 1/2 | NCT07631325 | Oct 2026 → Jul 2028 expected | cutaneous melanoma | John Kirkwood | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07281924 | Oct 2026 → Dec 2030 expected | metastatic melanoma | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06639607 | Sep 2026 → Aug 2031 | ependymoma, medulloblastoma | Washington University School of Medicine | Suspended | No outcome recorded |
| Phase 1/2 | NCT07679841 | Sep 2026 → Sep 2029 expected | vulvar squamous cell carcinoma | Centre Leon Berard | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07718243 | Aug 2026 → Jan 2030 expected | cutaneous melanoma, non-small cell lung carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07482059 | Feb → Jun 2026 overdue | hepatocellular carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07276373 | Jan → Sep 2026 overdue | neoplasm | Corcept Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07190027 | Nov 2025 overdue | non-small cell lung carcinoma | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06866262 | Aug 2025 → Aug 2031 expected | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07121374 | Jul 2025 → Jun 2028 expected | pleural epithelioid mesothelioma | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Show all 276 trials opens the full record — a long page | ||||||
| Phase 2715 trials · 36 met primary · 41 missed | ||||||
| Phase 2 | NCT07644312 | Mar 2027 → Mar 2033 expected | DNA repair disease, diffuse intrinsic pontine glioma, grade III glioma | Nationwide Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07862530 | Dec 2026 → Feb 2028 expected | cutaneous melanoma | Yana Najjar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07603856 | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07576725 | Dec 2026 → Aug 2029 expected | Hodgkins lymphoma, Kaposi's sarcoma, acral lentiginous melanoma, cervical cancer +10 | Fred Hutchinson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07689175 | Oct 2026 → Oct 2031 expected | hepatocellular carcinoma | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06365619 | Oct 2026 → Aug 2027 expected | melanoma | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT07820813 | Sep 2026 → Sep 2029 expected | — | Ole Schmeltz Søgaard | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06319196 | Aug 2026 → Feb 2027 expected | cutaneous melanoma, mucosal melanoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT07551583 | Aug 2026 → Dec 2030 expected | Hodgkins lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07546812 | Aug 2026 → Jan 2030 expected | Her2-receptor negative breast cancer, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Gilead Sciences | Recruiting | No outcome recorded |
| Show all 715 trials opens the full record — a long page | ||||||
| Phase 2/319 trials · 1 met primary · 3 missed | ||||||
| Phase 2/3 | NCT07572123 | Dec 2026 → Mar 2029 expected | classic Hodgkin lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07221149 | Mar 2026 → Nov 2030 expected | gastroesophageal adenocarcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06203600 | Jun 2024 → Oct 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05987241 | Feb 2024 → Sep 2030 expected | infiltrating bladder urothelial carcinoma, infiltrating renal pelvis/ureter urothelial carcinoma, urethra transitional cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05595447 | Oct 2022 → Oct 2025 overdue | Hodgkins lymphoma | Hospital Regional de Alta Especialidad del Bajio | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05213312 | Jun → Nov 2022 | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Unknown | Missed primary |
| Phase 2/3 | NCT04901988 | Nov 2021 → Jan 2023 | cutaneous melanoma | The Christie NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 2/3 | NCT04695977 | Feb 2021 → Jul 2024 | metastatic melanoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT04396860 | Sep 2020 → Jan 2023 | gliosarcoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2/3 | NCT04044651 | Oct 2019 → Mar 2021 | hepatocellular carcinoma | Shi Ming | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03952585 | Oct 2019 → Mar 2024 overdue | basaloid squamous cell carcinoma, oropharynx squamous cell carcinoma, papillary squamous carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04268888 | May 2019 → Aug 2025 | hepatocellular carcinoma | The Clatterbridge Cancer Centre NHS Foundation Trust | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03604991 | May 2019 → Mar 2027 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2/3 | NCT03879122 | Feb 2019 → Jul 2023 | metastatic prostate carcinoma | Spanish Oncology Genito-Urinary Group | Unknown | No outcome recorded |
| Phase 2/3 | NCT03470922 | Apr 2018 → Jan 2021 overdue | melanoma | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 2/3 | NCT03414983 | Feb 2018 → Feb 2021 | colorectal cancer | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 2/3 | NCT03092674 | Feb 2018 → Aug 2023 | acute myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT03366272 | Dec 2017 → Jan 2025 | non-Hodgkin lymphoma | Saarland University | Completed | No outcome recorded |
| Phase 2/3 | NCT02746796 | Mar 2016 → Jan 2020 | gastric cancer | Ono Pharmaceutical Co., Ltd. | Completed | Mixed |
| Phase 3116 trials · 30 met primary · 25 missed | ||||||
| Phase 3 | NCT07166406 | Feb 2026 → Mar 2029 expected | hepatocellular carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT07431281 | Feb 2026 → Aug 2029 expected | esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07174453 | Oct 2025 → Oct 2027 expected | — | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT07050043 | May 2025 → Dec 2030 expected | non-small cell lung carcinoma | Dr Arvindran A/L Alaga | Recruiting | No outcome recorded |
| Phase 3 | NCT06646276 | Feb 2025 → Apr 2028 expected | small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT06488482 | Dec 2024 → Sep 2030 expected | melanoma | Uppsala University | Recruiting | No outcome recorded |
| Phase 3 | NCT06632327 | Dec 2024 → Apr 2029 expected | non-small cell lung carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06490536 | Oct 2024 → Mar 2026 overdue | colorectal cancer | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06561386 | Oct 2024 → Jul 2030 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT06264180 | Jul 2024 → Sep 2030 expected | melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 412 trials | ||||||
| Phase 4 | NCT07459543 | Nov 2026 → May 2029 expected | metastatic melanoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07574047 | Sep 2026 → Jun 2030 expected | melanoma | Swiss Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06934057 | May 2025 → Apr 2028 expected | renal cell carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT05203172 | Jul 2022 → Jul 2029 expected | cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 4 | NCT06116461 | Jan 2022 → Oct 2024 | melanoma | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04513522 | Dec 2020 → Jan 2024 | kidney neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT04331626 | Apr 2020 → Dec 2022 | non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03444766 | Mar 2018 → Jul 2019 | kidney cancer, non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02982954 | Jan 2017 → May 2020 | renal cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02869789 | Oct 2016 → May 2022 | lung cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT02596035 | Jan 2016 → Mar 2018 | renal cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07233668 | Dec 2025 → Oct 2028 expected | renal cell carcinoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06341478 | Mar 2024 → Mar 2026 overdue | urinary bladder cancer | IRCCS San Raffaele | Recruiting | No outcome recorded |
| — | NCT06158919 | Nov 2023 → Nov 2024 overdue | gastroesophageal junction adenocarcinoma | Fudan University | Recruiting | No outcome recorded |
| — | NCT05652673 | Feb 2023 → Dec 2025 overdue | metastatic melanoma, poisoning | Erasmus Medical Center | Recruiting | No outcome recorded |
| — | NCT04845139 | Jul → Oct 2022 | central nervous system non-hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT07422779 | Mar 2022 → Mar 2027 expected | metastatic melanoma, skin cancer | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| — | NCT07428252 | Mar 2022 → Mar 2024 overdue | metastatic melanoma | Institute of Oncology Ljubljana | Active not recruiting | No outcome recorded |
| — | NCT07053202 | Oct 2021 → Nov 2022 | hepatocellular carcinoma | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
| — | NCT05001360 | Oct 2021 → Oct 2023 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Fujian Cancer Hospital | Withdrawn | No outcome recorded |
| — | NCT04801966 | Sep 2021 → Dec 2022 | cancer | Peter MacCallum Cancer Centre, Australia | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT05053295 | Jul 2021 → Jul 2023 | adenocarcinoma, gastroesophageal cancer | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT05745233 | Jan 2021 → Dec 2026 expected | peritoneal neoplasm | China Medical University Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT04603248 | Dec 2020 → Mar 2026 | head and neck squamous cell carcinoma | Yonsei University | Completed | No outcome recorded |
| — | NCT04256213 | Jul 2020 → Aug 2021 | cervical cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| — | NCT03035890 | Jan 2017 → Jun 2022 | non-small cell lung carcinoma | West Virginia University | Completed | No outcome recorded |
| — | NCT02833233 | Jun 2016 → Jun 2024 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT05063058 | Jan 2016 → Nov 2019 | melanoma | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02194738 | Sep 2014 → Dec 2025 overdue | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT02142218 | Jun 2014 → May 2018 | melanoma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT02475382 | — | non-small cell squamous lung carcinoma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT02186249 | — | melanoma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| Comparator or background therapy247 trials | ||||||
| Phase 0 | NCT07017816 Background | Dec 2025 → May 2028 expected | atypical teratoid rhabdoid tumor, ependymoma, malignant glioma, medulloblastoma +1 | Children's National Research Institute | Recruiting | No outcome recorded |
| Phase 0 | NCT05358938 Background | Jun 2022 → Oct 2024 overdue | cutaneous melanoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04570683 Comparator | Jan 2020 → Sep 2021 | allergic disease, basal cell carcinoma | Bispebjerg Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03371992 Background | Mar 2018 → Dec 2020 | non-small cell lung carcinoma | Nilogen Oncosystems | Unknown | No outcome recorded |
| Phase 1 | NCT07176975 Background | Aug 2027 → Dec 2028 | cancer | Boehringer Ingelheim | Suspended | No outcome recorded |
| Show all 247 trials opens the full record — a long page | ||||||
Press releases naming this drug 693 releases
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 1,769 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nivolumab | “Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the...” NCT05169957 ↗1700“EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered...” NCT04116658 ↗ “Standard of Care Drugs (at investigator's discretion) may include: pembrolizumab, nivolumab, cemiplimab, durvalumab, dostarlimab, avelumab, and atezolizumab, or other immune...” NCT07224971 ↗ “Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or...” NCT06903312 ↗ “This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor...” NCT03326752 ↗ “This editorial proposes that the TGF-β trap of AdAPT-001 reverses the immunosuppressive environment of tumor cells, and thus makes these tumors susceptible to CIs like the...” PMID 39461878 ↗ Oct 2024 “Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist...” NCT05846659 ↗ “Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR...” NCT04997837 ↗ “TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab,...” NCT02890368 ↗ “Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response,...” NCT05835804 ↗ “Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic...” NCT05350501 ↗ |
| Known as | ABP 206 | “ABP 206” NCT03811015 ↗1“ABP 206” NCT06064097 ↗ |
| Known as | BMS-936558 | “Nivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype mAb that binds PD-1 on activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7...” NCT04015778 ↗21“Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma” NCT02186249 ↗ “TITAN-TCC (0416-ASG) is a Phase 2, open-label study of nivolumab (BMS-936558) monotherapy with additional nivolumab/ipilimumab "boost" cycles” NCT03219775 ↗ “Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects” NCT02181738 ↗ “Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors” NCT02593786 ↗ “Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody” NCT02992964 ↗ “investigational drug called nivolumab (also known as BMS-936558) in glioblastoma” NCT03452579 ↗ “treated with Nivolumab (BMS-936558) at a dose of 3 mg/kg every two weeks.” NCT02156804 ↗ “Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care” NCT03075423 ↗ “nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody)” NCT02598960 ↗ “Relatlimab (BMS-986016) With Nivolumab (BMS-936558)” NCT04913922 ↗ |
| Known as | BMS-936558 (Nivolumab) | “BMS-936558 (Nivolumab)” NCT03143153 ↗1“BMS-936558 (Nivolumab)” NCT02869789 ↗ |
| Known as | BMS-936558-01 | “Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.” NCT04564157 ↗3“Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL)” NCT03177239 ↗ “Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)” NCT04572451 ↗ “Nivolumab (BMS-936558-01) Injection drug product” NCT05684276 ↗ |
| Known as | BMS-986298 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108738 ↗ |
| Known as | Identification code of the investigational drug; BMS-936558, MDX1106, ONO-4538 | “Identification code of the investigational drug; BMS-936558, MDX1106, ONO-4538” NCT03406871 ↗ |
| Known as | MDX1106 | “Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody” NCT02992964 ↗3“The antiviral potential of BMS-936558 (MDX-1106)” PMID 23717490 ↗ May 2013 “BMS-936558 (MDX-1106)” NCT01024231 ↗ |
| Known as | MDX1106-04 | “BMS-936558 (MDX1106-04)” NCT01024231 ↗ |
| Known as | NIVO | “In the MATISSE trial, the primary objective was met to investigate the pathological response rate on neoadjuvant nivolumab (NIVO) and nivolumab plus ipilimumab (NIVO + IPI) at...” PMID 41062829 ↗ Oct 202526“We conducted a multicenter, open-label, randomized phase 2 study to assess the efficacy of nivolumab (Nivo) as maintenance therapy for patients with acute myeloid leukemia...” PMID 39928953 ↗ May 2025 “CA209-7AL is a randomized, multicenter, phase 2 trial evaluating the efficacy and safety of consolidative nivolumab (NIVO) versus observation following neoadjuvant NIVO plus...” PMID 41016926 ↗ Sep 2025 “This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab...” PMID 34255535 ↗ Jul 2021 “The aim of this open-label, phase III CheckMate 498 study was to evaluate the efficacy of nivolumab (NIVO) + RT compared with TMZ + RT in newly diagnosed GBM with unmethylated...” PMID 35419607 ↗ Jan 2023 “NRG Oncology BN002 (phase I) demonstrated safety and suggested efficacy of ipilimumab (ipi) with nivolumab (nivo) in newly diagnosed glioblastoma, leading to this phase II/III trial.” PMID 40779733 ↗ Aug 2025 “BACKGROUND: As for squamous (Sq)-NSCLC, Checkmate-017 trial showed a significant overall survival (OS) improvement in favor of Nivolumab (Nivo) over Docetaxel in 2nd-line.” PMID 39700681 ↗ Dec 2024 “This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.” NCT06712927 ↗ “PURPOSE: Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma.” PMID 39504507 ↗ Nov 2024 “OBJECTIVE: To investigate the safety and antitumor activity of SEL, nivolumab (NIVO), and ipilimumab (IPI) in Asian patients with treatment-refractory solid organ cancers.” PMID 40502306 ↗ Jun 2025 “We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers.” PMID 38252910 ↗ Jan 2024 |
| Known as | Nivolimumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03278626 ↗ |
| Known as | Nivolumab (OPDIVO) | “Nivolumab (OPDIVO)” NCT02460068 ↗3“nivolumab (Opdivo)” NCT04250246 ↗ “nivolumab (OPDIVO)” NCT03009058 ↗ “nivolumab (opdivo)” NCT03026140 ↗ |
| Known as | Nivolumab (Opdivo) BMS-936558-01 | “Nivolumab (Opdivo) BMS-936558-01” NCT03003637 ↗ |
| Known as | Nivolumab + Relatlimab FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07492680 ↗ |
| Known as | Nivolumab and Recombinant Human Hyaluronidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383441 ↗ |
| Known as | Nivolumab Biosimilar BCD-263 | “Nivolumab Biosimilar BCD-263” NCT06029270 ↗ |
| Known as | Nivolumab Biosimilar CMAB819 | “Nivolumab Biosimilar CMAB819” NCT06029270 ↗ |
| Known as | Nivolumab bms | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108738 ↗ |
| Known as | Nivolumab component of bms-986213 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108738 ↗ |
| Known as | Nivolumab component of opdualag | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108738 ↗ |
| Known as | Nivolumab Injection | “A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil...” NCT06022861 ↗ |
| Known as | Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538; | “Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538;” NCT04326257 ↗ |
| Known as | NSC# 748726 | “A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old...” NCT04546399 ↗ |
| Known as | odiwal | “Bristol-myers squibb (BMS) company's nivolumab injection liquid (trade name: odiwal).” NCT04331626 ↗ |
| Known as | ONO-4538 | “ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.” NCT03117049 ↗ |
| Known as | Opdivo | “This phase I/Ib trial will assess the dose, safety and side effects of the combination of the cancer drugs afatinib (GILOTRIF®) and nivolumab (OPDIVO®) and to assess the...” NCT03652233 ↗59“This phase 1b/2 study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients with of...” NCT04165330 ↗ “Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated...” NCT03575598 ↗ “Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1...” NCT07121374 ↗ “The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a...” NCT04187833 ↗ “A Pilot Study of Alectinib (Alecensa) in Combination With Nivolumab (Opdivo) in the Treatment of Recurrent or Refractory Hepatocellular Carcinoma Patients Guided With Serum...” NCT06354387 ↗ “Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.” NCT03557359 ↗ “Nivolumab injection OPDIVO® will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.” NCT03984357 ↗ “Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.” NCT07176650 ↗ “Nivolumab (Opdivo®)- an anti-PD1 treatment- combined to tisagenlecleucel in a cohort of relapsed or refractory B-ALL patients” NCT05310591 ↗ “One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes” NCT03685890 ↗ |
| Known as | Opdivo (Nivolumab) | “Opdivo (Nivolumab)” NCT03143153 ↗1“Opdivo (Nivolumab)” NCT02869789 ↗ |
| Known as | Opdivo (trade name for Nivolumab) | “Opdivo (trade name for Nivolumab)” NCT04107103 ↗ |
| Known as | OpdivoTM | “Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.” NCT04021108 ↗2“Nivolumab (OpdivoTM, BMS), a human IgG-4 mAb that blocks the Programmed cell death protein 1 (PD-1, CD279) has demonstrated anti-tumor activity” NCT03233152 ↗ “Nivolumab (OpdivoTM, 40 mg/4mL solution)” NCT07230613 ↗ |
| Known as | Optiva (nivolumab) | “Optiva (nivolumab)” NCT04157985 ↗ |
| Known as | OPTIVO | “Nivolumab (Optivo®)” NCT04343144 ↗ |
| Known as | Single agent Nivolumab | “Single agent Nivolumab” NCT04042753 ↗ |
| Action | Inhibit | “blocks ligand binding” PMID 23717490 ↗ May 2013 |
| Modality | Monoclonal antibody | “fully human anti-PD-1 monoclonal” PMID 23717490 ↗ May 2013 |
| Route | Intravenous | “single intravenous (IV) infusion” NCT00441337 ↗ |
| Target | PDCD1 | “anti-programmed cell death 1 (anti-PD-1) therapy” PMID 33914706 ↗ Jun 2021 |